Intelligent Bio Solutions INC 8-K filings

Intelligent Bio Solutions Inc. announced a 50% year-over-year increase in new customer accounts, adding 33 in its fiscal first quarter and bringing total active accounts to over 480.

Intelligent Bio Solutions Inc. stockholders approved an expanded long-term incentive plan and authorized a potential reverse stock split to maintain Nasdaq listing compliance.

Intelligent Bio Solutions Inc. announced a revised timeline for FDA 510(k) clearance of its fingerprint drug screening system, now anticipated in H2 2026.

Intelligent Bio Solutions Inc. has extended the termination date for its Series H-1 Common Stock Purchase Warrants from September 27, 2025, to March 27, 2026, with no change to exercise prices or other terms.

Intelligent Bio Solutions Inc. announced a delay in FDA 510(k) clearance for its fingerprint drug screening system, requiring a new submission.

Intelligent Bio Solutions Inc. announced its fiscal 2025 fourth quarter and full-year results, highlighting progress on U.S. market expansion and revenue growth in Q4, despite a full-year net loss increase and significant cash reduction.

Intelligent Bio Solutions Inc. announced preliminary fiscal fourth quarter 2025 revenue growth of approximately 16% sequentially and year-over-year, alongside significant progress on U.S. FDA 510(k) clearance for its opiate test system.

Intelligent Bio Solutions Inc. submitted its Additional Information response to the FDA, strengthening its 510(k) clearance package for U.S. market entry.

Intelligent Bio Solutions Inc. announced a warrant inducement offer expected to generate approximately $3.8 million in gross proceeds to fund its FDA 510k filing for the Fingerprint Drug Screening System.

Intelligent Bio Solutions Inc. announced the successful collection of new data reinforcing the security and performance of its Intelligent Fingerprinting Drug Screening System, strengthening its FDA 510(k) submission.

Intelligent Bio Solutions Inc. announced a new global distribution agreement with SMARTOX to bring its SmarTest Patch drug detection product to international markets outside the U.S. and Canada, reinforcing its position in non-invasive drug testing.

Intelligent Bio Solutions Inc. announced the strategic addition of the SmarTest Patch, a wearable device enabling continuous drug detection through sweat over 7 to 10 days, significantly expanding its non-invasive testing solutions.

Intelligent Bio Solutions Inc. has amended the employment agreements for its President and CEO, Harry Simeondis, and CFO, Spiro Sakiris, increasing their base salaries and enhancing severance benefits, particularly in the event of a Change in Control.

Intelligent Bio Solutions Inc. announces significant growth in global operations, exceeding 450 active accounts across 24 countries due to increased adoption of its fingerprint drug testing system.

Intelligent Bio Solutions Inc. announced a 20% sequential quarterly revenue increase and a 91% year-over-year gross profit increase for fiscal Q3 2025, fueled by growing cartridge sales and customer acquisition.

Intelligent Bio Solutions has been granted a U.S. patent for its Intelligent Fingerprinting Drug Screening Cartridge, strengthening its intellectual property protection ahead of its planned 2025 U.S. market entry.

Intelligent Bio Solutions Inc. provides an update on its FDA clearance process for its Intelligent Fingerprint Drug Screening System, reaffirming its planned U.S. launch in 2025.

Intelligent Bio Solutions expects to receive its sixth U.S. patent, strengthening protection for its fingerprint-based drug testing technology.

Intelligent Bio Solutions Inc. announces the date and record date for its 2024 annual meeting of stockholders, along with deadlines for shareholder proposals and director nominations.

Intelligent Bio Solutions Inc. has filed a prospectus supplement to offer and sell up to $1,376,530.39 of its common stock under an existing At-The-Market Offering Agreement.

Intelligent Bio Solutions Inc. closed a public offering of common stock, raising $3 million after the underwriter fully exercised their option to purchase additional shares.

Intelligent Bio Solutions Inc. announced its fiscal Q2 2025 financial results, showcasing a 32.6% increase in gross profit and progress towards entering the U.S. market.

Intelligent Bio Solutions recapped its 2024 growth, highlighting a 148% year-over-year revenue increase and its plans for U.S. market expansion in 2025 following FDA 510(k) submission.

Intelligent Bio Solutions Inc. (INBS) partners with Avon Freight Group to implement its fingerprint drug testing solution across three UK sites, signaling growth and a focus on U.S. expansion.

Intelligent Bio Solutions expects a 32.6% increase in gross profit and improved profitability driven by higher-margin cartridge sales.

Intelligent Bio Solutions announces a major upgrade to its drug screening system, adding multilingual support to reach over 4 billion users globally.

Quantum Traffic Management, a UK-based traffic management provider, has adopted Intelligent Bio Solutions' fingerprint drug testing solution to improve workplace testing efficiency and safety across its 10 nationwide sites.

Intelligent Bio Solutions partners with IVY Diagnostics to expand its drug screening technology into the European and Middle Eastern markets.

Intelligent Bio Solutions Inc. reports a total of 4,807,068 outstanding shares of common stock as of January 2, 2025, following recent equity sales and stock issuances.

Intelligent Bio Solutions has submitted its 510(k) premarket notification to the FDA for its fingerprint-based drug screening system, marking a significant step towards US market entry.